Frontlight ResearchEarly access
CompletedPhase 4
Aspirin to prevent cardiovascular events in patients with pneumonia or influenza
Key facts
- Who runs it
- Amsterdam UMC
- Where
- Netherlands16 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 760 people enrolled
- Started
- 27 Dec 2023
- Ended
- 30 Jun 2026
- Type of study
- Interventional
- Record updated
- 9 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 40 years or older
- Any of the following respiratory infections: moderate to severe community-acquired pneumonia (defined as clinical signs of pneumonia, radiological evidence of a new infiltrate consistent with pneumonia, and severity score CURB-65 score ≥2 or PSI score ≥3) or influenza (defined as clinical signs of a respiratory infection and a positive influenza PCR test result)
- Admitted to hospital
Who cannot take part
- Conditions which require antiplatelet therapy
- Contraindications for aspirin: recent (<1 month) hemorrhagic CVA, recent major gastro-intestinal bleeding or other hemorrhage, active bleeding, thrombocytopenia < 100, known hemorrhagic diathesis, allergy for salicylates
- Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP>110 mm Hg)
- Use of vitamin K antagonists, direct oral anticoagulants or therapeutic LMWH
- Life expectancy less than one month
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate whether adding aspirin to standard therapy in patients with moderate to severe community-acquired pneumonia or influenza will reduce the incidence of acute coronary syndrome in hospitalized patients
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Aspirin to prevent cardiovascular events in patients with community-acquired pneumonia or influenza
- Record updated
- 9 October 2025